Stock Ratings / Health Care / ALMR / insiders

PACB (44) CTKB (45) BRKR (59) BIO (66) ⌘ Pro Terminal →

Alamar Biosciences Inc. (ALMR) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$34.04 -0.76% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $33.93

Alamar Biosciences Inc. (ALMR) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $2.36B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ALMR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ALMR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Alamar Biosciences Inc. (NASDAQ: ALMR) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $34.04 (-0.76% 1D, market cap $2.36B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 16/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ALMR compare to PACB and CTKB in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), ALMR carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, PACB (Pacific Biosciences of California Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $901.4M) and CTKB (Cytek Biosciences Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -12.7%, cap $818.9M). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while BRKR leads on capital efficiency (1.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ALMR?

▼

Per ALMR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002104204), Alamar Biosciences Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $140.0M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $33.93 (-0.33%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 1.7% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALMR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (61/100 Composite)

🔍 WHY ALMR SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+16/20 pts (26% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$24.24+8.5% Next Q

Q2 (-2Q)

Grade C$26.30+15.6% Next Q

Q3 (-1Q)

Grade C$30.39+12% Next Q

Current

Grade C-$34.04+0.5% Hist 90D α

Trajectory: C- (53) → C- (61)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ALMR Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 61/100 (C-) score, ALMR faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($30.64) or 200D SMA ($26.98) invalidates the momentum regime and cuts Target Base ($34.50) toward Bear Floor ($26.91).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALMR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ALMR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 61%NO 39%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

ALMR Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (ALMR)

No recent open-market Form 4 cluster sales or emergency dumps flagged on ALMR. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (ALMR Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ALMR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +43.27%▲ ASCENDING CHANNEL

2026-11-02O $34.30H $34.30L $34.04C $34.04VOL 496.2K

RES: $40.13SUP: $23.53SMA50: $30.64SMA200: $26.98

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALMR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALMR Butterfly Map → + Track ALMR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ALMR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALMR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ALMR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALMR)

Health Care Rank #169 of 1016 ⚔️ PACB vs ALMR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALMR vs. PACB, CTKB, BRKR, BIO)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Alamar Biosciences Inc. (ALMR) ranks #169 by composite RQD confidence (61/100, grade C-) and #230 by equity capitalization ($2.36B). Within this direct 5-issuer industry benchmark cohort, BIO leads on earnings valuation at 13.5x trailing P/E, while BRKR leads on capital efficiency and profitability with 1.3% ROIC and 45.9% gross margin. BIO currently holds the highest overall quantitative score in the immediate peer group at 66/100 (C+) compared with ALMR at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ALMR ACTIVE Alamar Biosciences Inc.	C-	61/100	—	—	—	-0.76%	$2.36B	Benchmark Subject
PACB Pacific Biosciences of California Inc.	D	44/100	—	28.6%	-35.0%	+2.47%	$901.4M	/pacb-vs-almr →
CTKB Cytek Biosciences Inc.	D	45/100	—	51.8%	-12.7%	+2.61%	$818.9M	/ctkb-vs-almr →
BRKR Bruker Corporation	C-	59/100	—	45.9%	1.3%	0.00%	$9.45B	/brkr-vs-almr →
BIO Bio-Rad Laboratories Inc.	C+	66/100	13.5x	51.9%	0.5%	-0.19%	$10.28B	/bio-vs-almr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002104204

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Alamar Biosciences Inc. (ALMR) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, ALMR closed FY2025 with $140.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$140.0M	—

3. ALMR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALMR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ALMR compare to PACB and CTKB in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ALMR?

Where is ALMR trading relative to its 50-day, 200-day, and 52-week technical levels?

ALMR last traded at $34.04 (-0.76% on volume of 496,166 shares), positioning the stock +11.10% above its 50-day simple moving average ($30.64) and +26.17% above its 200-day simple moving average ($26.98). Across its 52-week range of $18.85 to $39.61, ALMR sits at the 73.2% percentile with a 14-day RSI of 57.5 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($29.79 to $38.29).

ALMR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are ALMR insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies ALMR leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: ALMR RQD Cockpit ALMR 12M Forecast ALMR Earnings & Move ALMR Dividends & DRIP ALMR Insiders & 13F ALMR Whale Options ALMR Profit Sankey ALMR News & Why